Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Editorial introduction: The role of ART as prevention of HIV transmission at a population level has become a more recent area of interest.

[No authors listed]

Curr Opin HIV AIDS. 2010 Jul;5(4):iv. doi: 10.1097/COH.0b013e32833b64e7. No abstract available.

PMID:
20539085
2.

HIV-2 down, HIV-1 to go? Understanding the possibilities of treatment as prevention.

Bruhn CA, Gilbert MT.

Lancet Infect Dis. 2011 Apr;11(4):260-1. doi: 10.1016/S1473-3099(11)70037-8. No abstract available.

PMID:
21453865
3.

Antiretroviral therapy for naïve and for treatment-experienced HIV patients, and prevention of HIV transmission.

Antunes F.

Curr Opin HIV AIDS. 2011 Dec;6 Suppl 1:S1-2. doi: 10.1097/01.COH.0000410241.73270.df. No abstract available.

PMID:
22156774
4.

Uptake of biomedical interventions for prevention of sexually transmitted HIV.

Abbas UL.

Curr Opin HIV AIDS. 2011 Mar;6(2):114-8. doi: 10.1097/COH.0b013e328343ad7e. Review.

PMID:
21505385
5.

HIV-1 treatment as prevention: the good, the bad, and the challenges.

Smith K, Powers KA, Kashuba AD, Cohen MS.

Curr Opin HIV AIDS. 2011 Jul;6(4):315-25. doi: 10.1097/COH.0b013e32834788e7. Review.

6.

25 years after HIV discovery: prospects for cure and vaccine.

Montagnier L.

Virology. 2010 Feb 20;397(2):248-54. doi: 10.1016/j.virol.2009.10.045. Review. No abstract available.

7.

Projecting the benefits of antiretroviral therapy for HIV prevention: the impact of population mobility and linkage to care.

Andrews JR, Wood R, Bekker LG, Middelkoop K, Walensky RP.

J Infect Dis. 2012 Aug 15;206(4):543-51. doi: 10.1093/infdis/jis401. Epub 2012 Jun 18.

8.

Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update.

Granich R, Crowley S, Vitoria M, Smyth C, Kahn JG, Bennett R, Lo YR, Souteyrand Y, Williams B.

Curr Opin HIV AIDS. 2010 Jul;5(4):298-304. doi: 10.1097/COH.0b013e32833a6c32. Review.

9.

Fertility intentions and interest in early antiretroviral therapy among East African HIV-1-infected individuals in serodiscordant partnerships.

Mujugira A, Heffron R, Celum C, Mugo N, Nakku-Joloba E, Baeten JM; Partners PrEP Study Team..

J Acquir Immune Defic Syndr. 2013 May 1;63(1):e33-5. doi: 10.1097/QAI.0b013e318288bb32. No abstract available.

10.

Optimizing the engagement of care cascade: a critical step to maximize the impact of HIV treatment as prevention.

Hull MW, Wu Z, Montaner JS.

Curr Opin HIV AIDS. 2012 Nov;7(6):579-86. doi: 10.1097/COH.0b013e3283590617. Review.

PMID:
23076123
11.

HIV prevention 2010: where are we now and where are we going?

Cohen MS, Fidler S.

Curr Opin HIV AIDS. 2010 Jul;5(4):265-8. doi: 10.1097/COH.0b013e32833acafa. No abstract available.

PMID:
20539086
12.

Treatment as prevention for HIV: a reality.

Blaxhult A, Bratt G.

AIDS. 2015 Aug 24;29(13):1721. doi: 10.1097/QAD.0000000000000759. No abstract available.

PMID:
26372285
13.

Reaping the prevention benefits of highly active antiretroviral treatment: policy implications of HIV Prevention Trials Network 052.

Forsyth AD, Valdiserri RO.

Curr Opin HIV AIDS. 2012 Mar;7(2):111-6. doi: 10.1097/COH.0b013e32834fcff6. Review.

PMID:
22227586
14.

CROI 2014: Advances in antiretroviral therapy.

Taylor BS, Shalev N, Wilkin TJ.

Top Antivir Med. 2014 May;22(2):616-31. Review.

15.

The potential impact of expanding antiretroviral therapy and combination prevention in Vietnam: the modeling approach.

Suthar AB, Bui DD, Granich RM, Nadol P, Tran HV, Sabin K, Williams BG, Lo YR, Kato M.

J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):e62-3. doi: 10.1097/QAI.0000000000000139. No abstract available.

PMID:
24828271
16.

What does preexposure prophylaxis mean for treatment; what does treatment mean for preexposure prophylaxis?

Venter WD.

Curr Opin HIV AIDS. 2016 Jan;11(1):35-40. doi: 10.1097/COH.0000000000000208. Review.

PMID:
26545265
17.

Treatment to prevent transmission of HIV-1.

Cohen MS, Gay CL.

Clin Infect Dis. 2010 May 15;50 Suppl 3:S85-95. doi: 10.1086/651478. Review.

18.

Assessing the Public Health impact of HIV interventions: the critical role of demographics.

Dimitrov D, Kuang Y, Mâsse BR.

J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):e60-2. doi: 10.1097/QAI.0000000000000133. No abstract available.

19.

Implications of the Henan Province report on the treatment as prevention debate.

Montaner J, Hogg R.

J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):e101; author reply e101-2. doi: 10.1097/QAI.0b013e318202e41d. No abstract available.

PMID:
21317576
20.

Condom use among antiretroviral therapy patients in Ibadan, Nigeria.

Akinyemi JO, Awolude OA, Adewole IF, Kanki PJ.

J Infect Dev Ctries. 2010 Sep 3;4(8):495-502.

Supplemental Content

Support Center